Literature DB >> 16750120

Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies.

Albert Roger Reig1, M Josep Plazas Fernández, Jordi Galván Cervera, Joan Heras Navarro, Maite Artés Ferragud, Elia Gabarrón Hortal.   

Abstract

BACKGROUND: One of the factors affecting compliance is the pharmaceutical formulation used. Many patients find it difficult to swallow tablets or capsules. The fast dissolving tablet (FDT) formulation could help to enhance patient compliance, because of its ease of administration and because no liquid is required to help intake.
MATERIAL AND METHODS: A survey was conducted in patients diagnosed with allergic rhinitis or dermatitis (positive skin tests and/or specific IgE) and urticaria to asses the degree of acceptance of and preference for an FDT formulation.
RESULTS: Of the 7,686 patients who participated in the survey, 90 % considered the initial flavor and 83 % considered the aftertaste to be very or quite satisfactory, 95 % were very satisfied with the disintegration time, 79 % were very satisfied with the form, 82 % with the size, 72 % with the packaging and 78 % with the instructions for use. Ninety-three percent considered that being able to take the drug at any time or place was very important or fairly important. Ninety-four percent considered the ease of use to be much better or better. If given the choice, 93 % would choose an FDT formulation. Eighty-eight percent of the patients would like to change their current antihistaminic drug for a new allergy drug in an FDT formulation.
CONCLUSIONS: Most of the patients were highly satisfied with the characteristics of the FDT formulation and would choose it for the treatment of their allergies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750120     DOI: 10.1157/13088176

Source DB:  PubMed          Journal:  Allergol Immunopathol (Madr)        ISSN: 0301-0546            Impact factor:   1.667


  4 in total

1.  Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.

Authors:  Carlos Martín de Argila; Julio Ponce; Emilio Márquez; M José Plazas; Jordi Galván; Joan Heras; Joana Porcel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Explorative study on patient's perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis.

Authors:  Peter W Hellings; Fabienne Dobbels; Kris Denhaerynck; Mark Piessens; Jan L Ceuppens; Sabina De Geest
Journal:  Clin Transl Allergy       Date:  2012-05-29       Impact factor: 5.871

3.  Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.

Authors:  S Rico; Rm Antonijoan; Mj Barbanoj
Journal:  J Asthma Allergy       Date:  2009-08-31

Review 4.  Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management.

Authors:  C Bachert; J Bousquet; P Hellings
Journal:  Clin Transl Allergy       Date:  2018-06-25       Impact factor: 5.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.